MONOJO Biotech

Company overview

MONOJO was established in 2005 to become a leader company in biotechnology. The company now epitomises the new concept of the knowledge-based economy.

MONOJO is dedicated on developing, manufacturing, and marketing its own safe and effective biotech innovations, such as, monoclonal antibodies for cancer diagnostics, cancer research, and other novel biopharmaceutical therapies to meet serious worldwide unmet needs and illnesses in the field of oncology, endocrinology, dermatology, gastroenterology, and infectious diseases.

MONOJO also provides unique training courses in the biotech and medical fields for public universities, medical sectors, and those running applied scientific research.

By 2009, MONOJO started to expand its biotech projects for more effective and efficient work by signing a MOU agreement with the Institute of Biotechnology of the University of Cambridge, UK, represented by its institute’s director and member of MONOJO’s Board of Directors and Scientific Advisor, Prof. Christopher Lowe for the purpose of collaboration in:

• Facilitating experts and students from Cambridge Biotech Institute (UK) to share their expertise and knowledge.

• Assisting MONOJO to increase its research capability through scientific visits and training for MONOJO staff either in-house or at the Cambridge Biotech Institute (UK).

• Facilitating collaborative biotech research and projects between MONOJO and the University of Cambridge (UK).

MONOJO is currently a member of the UK BioIndustry Association; the association has enhanced MONOJO’s visibility, network, and relationships with business decision-makers in the UK and European bioscience industry.

The company operates in two main countries, in Jordan at our headquarters The MONOJO, where it constitutes the main company’s research and development (R&D) and its global business development and marketing operations department for its innovative bioproducts. Its second main base of operations is in the USA where MONOJO’s first subsidiary The Columbia Biotech complements MONOJO’s R&D Department and its business development and marketing operations.

MONOJO offers challenging and stimulating envi-ronments in which individuals can work together to build on their diverse strengths, delivering their personal best, and making significant contributions to worldwide communities.

MONOJO departments: scope of activities and services

Clinical trials

MONOJO is dedicated to develop, manufacture, and marketing newly innovative therapies to treat serious illnesses along with careful ethical procedures according to current international guidelines. One of these procedures is clinical trials.

MONOJO haing finished its preclinical trials is looking to begin clinical trial with the best CRO (Phase I, II and III) on volunteers (patients) in order to observe the effectiveness of its novel therapies on human subjests and their possible adverse side effects.

Corporate responsibility

The Applied Scientific Research Fund (ASRF) is a spin off non-profit organization from MONOJO, created and initially funded by Dr. Samih Darwazeh, the founder of Hikma Pharmaceuticals and chairman of MONOJO, to promote the development of applied science and engineering ideas. Our main target investigators are colleges and universities in many fields such as medicine, natural sciences, engineering, information technology and many others.

ASRF is the first research funding organization initiated from the private sector in Jordan as a non-profit company acting on a commercial basis while 100% of the profit is invested back in the fund to support the creation of the innovation ecosystem in Jordan and the Middle East. We at ASRF are applying and experimenting new innovation funding approaches in the Middle East while focusing on sustainability. ASRF will fund applied researches and innovations that have market potential and the return on investment will be through intellectual property commercialization.

URL: www.asrf.jo

Certificates

MONOJO has been approved by Lloyds Register Quality Assurance for the following Quality Management System Standards:

• ISO 13485:2003

  • The quality management system is applicable to “Production of IVD’s: Antibodies”

• ISO 9001: 2008

  • The quality management system is applicable to “Production of IVDs: antibodies and provision of practical biotech courses”

Board of directors

MONOJO’s board of directors brings together a group of highly experienced entrepreneurs, scientists and venture capital investment representatives.

• Chairman: Dr. Samih Darwazeh

• Vice Chairman: Dr. Marwan Kamal

• Member: Prof. Chris Lowe

• Member: Mrs. Penelope Shihab

• Member: Dr. Feras Al-Alaaly

Management team

MONOJO’s team expertise brings together a wealth of multidisciplinary talent

• CEO & Founder: Mrs. Penelope Shihab

• The Financial & Administrative Manager: Mr. Sameer Nasrallah

• R&D Manager: Dr. Khalid Al-Qaoud

• Microbiology Section Head: Dr. Luay Abu Qatouseh

• Training Manager: Mrs. Abeer Awad

• Business Development Manager: Mr. Mohammad Abu-Zaid

Key investors

• Dr. Samih Darwazeh

• The Higher Council for Science and Technology – HCST

• Royal Scientific Society – RSS

• Jordan University for Science and Technology – JUST

• Philadelphia University

• Petra University

• Al-Nahil Group

• University of Jordan

• Yarmouk University

National strategic alliance

• Jordan University of Science and Technology

• Yarmouk University

• University of Jordan

• Hashemite University

Locations and spin offs

• Amman City, Jordan

  • THE MONOJO “Jordan Company for Antibody Production” (Head Quarter)

  • The Applied Scientific Research Fund – ASRF (Spin Off from MONOJO)

• Columbia, MS, USA

  • COLUMBIA BIOTECH (US MONOJO’s Subsidiary)

  • Contact : Tel : +962 6 5161398

  •    +962 6 5155078

  •    +962 6 5155095

  •   Fax : +962 6 5161399

  •   P.O.Box 675 Al-Jubaiha 11941 Jordan

  •   E-mail: info@monojo.com.jo

  •   www.monojo.com.jo